Some studies demonstrated that THZ1, a covalent CDK7 inhibitor, can indeed suppress master transcription-regulating oncogenes, such as MYC, in neuroblastoma models[123,124], and Zhang et al.[81] expanded the study to several myeloma cell lines, reporting a potent antiproliferative and proapoptotic effect with exposure times as little as 24 h and even in the context of resistance to bortezomib. The gene discussed is MYC; the disease is plasma cell myeloma.